Wegener's Granulomatosis vasculitis and granuloma

Autoimmunity Reviews

Volumn 9, Issue 7, 2010, Pages 483-487

  Schilder, Anna M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Granuloma; PR3 ANCA; Th1; TNFalpha; Vasculitis; Wegener's Granulomatosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; CYTOTOXIN;

ANCA ASSOCIATED VASCULITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL MATURATION; CLINICAL TRIAL; CROHN DISEASE; CYSTITIS; CYTOTOXICITY; DRUG MEGADOSE; ENDOTHELIUM CELL; GRANULOMA; HUMAN; HYPOGONADISM; MORTALITY; NEUTROPHIL; PATHOGENESIS; PLASMAPHERESIS; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULITIS; WEGENER GRANULOMATOSIS; ANIMAL; BIOLOGICAL THERAPY; CHORISTOMA; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; INFLAMMATION; LYMPHOID TISSUE; PATHOPHYSIOLOGY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL THERAPY; CHORISTOMA; CYTOTOXINS; GRANULOMA; HUMANS; INFLAMMATION; LYMPHOID TISSUE; MYELOBLASTIN; RECURRENCE; STEM CELL TRANSPLANTATION; WEGENER GRANULOMATOSIS; GRANULOMATOSIS WITH POLYANGIITIS;

EID: 77951879468     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.02.006     Document Type: Review

References (40)

1. Voswinkel J., Muller A., and Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions?. Ann N Y Acad Sci 1051 (2005) 12-19
2. Kallenberg C.G., and Tadema H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to "autoimmunity and infection". Autoimmun Rev 8 (2008) 29-32
3. Mohammad A.J., Jacobsson L.T., Mahr A.D., Sturfeld G., and Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in Southern Sweden. Rheumatology 46 (2007) 1329-1337
4. Langford C.A., and Hoffman G.S. Rare diseases. 3: Wegener's granulomatosis. Thorax 54 (1999) 629-637
5. Hoffman G.S., and Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41 (1998) 1521-1537
6. Stone J.H. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 48 (2003) 2299-2309
7. Walton E.W. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 34 (1958) 265-270
8. De Groot K., Harper L., Jayne D.R.W., Suarez L.F.P., Gregorini G., Gross W.L., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med 150 (2009) 670-680
9. Reinhold-Keller A., Beuge N., Latza U., De Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 43 (2000) 1021-1032
10. Hellmich B., Lamprecht P., and Gross W.L. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 18 (2006) 25-32
11. De Groot K., Harper L., Jayne D.R.W., Suarez L.F.P., Gregorini G., Gross W.L., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med 150 (2009) 670-680
12. Reinhold-Keller A., Beuge N., Latza U., De Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 43 (2000) 1021-1032
13. Hu N., Westra J., and Kallenberg C.G.M. Membrane-bound proteinase 3 and its receptors: relevance for the pathogenesis of Wegener's Granulomatosis. Autoimmun Rev 8 (2009) 510-514
14. Witko-Sarsat V., Lesavre P., Lopez S., Bessou G., Hielbot C., Prum B., et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 10 (1999) 1224-1233
15. Rarok A.A., Stegeman C.A., Limburg P.C., and Kallenburg C.G. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 13 (2002) 22320-22328
16. Kettritz R., Schreiber A., Luft F.C., and Haller H. Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 12 (2001) 37-46
17. Porges A.J., Redecha P.B., Kimberly W.T., Csernok E., Gross W.L., and Kimberly R.P. Anti-neutrophil cytoplasmic autoantibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 153 (1994) 1271-1280
18. Falk R., Terrel R.S., Charles L.A., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87 (1990) 4115-4119
19. Condliff A.M., Chilvers E.R., Haslett C., and Dransfield I. Priming differentially regulates neutrophil adhesion molecule expression/function. Immunology 89 (1996) 105-111
20. Savage C.O.S., Pottinger B.E., Gaskin G., Pusey C., and Pearson J.D. Autoantibodies developing to MPO and PR3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J Pathol 141 (1992) 335-342
21. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Nephrol 18 (2007) 2180-2188
22. Reinhold-Keller A., Beuge N., Latza U., De Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum 43 (2000) 1021-1032
23. Seo P., Min Y., Holbrook J.T., Hoffman G.S., Merkel P.A., Spiera R., et al. Damage caused by Wegener's granulomatosis and its treatment. Prospective data from the Wegener's granulomatosis etanercept trial (WGET). Arthritis Rheum 52 (2005) 2168-2178
24. Wegener's Granulomatosis Etanercept Trial (WEGT) Research group. Etanercept plus standard therapy for Wegener's Granulomatosis. N Eng J Med 352 (2005) 352-361
25. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Bearg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
26. Booth A., Harper l., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Nephrol 15 (2004) 717-721
27. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
28. Omdal R., Wildhagen K., Hansen T., Gunnarsson R., and Kristoffersen G. Anti-CD20 therapy of treatment resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34 (2005) 229-232
29. Wong C.F. Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol 14 (2008) 61-64
30. Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 (2006) 853-858
31. Voswinkel J., Muller A., and Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions?. Ann N Y Acad Sci 1051 (2005) 12-19
32. Csernok E., Trabandt A., Muller A., Wang G.C., Moosig F., Paulsen J., et al. Cytokine profiles in Wegener's granulomatosis. Arthritis Rheum 42 (1999) 742-750
33. Csernok E., Moosig F., and Gross W.L. Pathways to ANCA production: from differentiation of dendritic cells by proteinase 3 to B lymphocyte maturation in Wegener's granuloma. Clinic Rev Allerg Immunol 34 (2008) 300-306
34. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-Suarez L.F., Van der Woude F.J., et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65 (2004) 1440-1448
35. Lockwood C.M. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 32 (1998) 473-478
36. Mannon P.J., Fuss I.J., Mayar L., Elson A.O., Sandborn W.J., Present D., et al. Anti-Interleukin-21 antibody for active Crohn's disease. New Eng J Med 351 (2004) 2069-2079
37. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135 (2008) 1130-1141
38. Ludviksson B.R., Sneller M.C., Chua K.S., Talar-Williams C., Langford C.A., Ehrhardt R.O., et al. Active Wegener's granulomatosis is associated with HLA-DR + CD4+ T cells exhibiting an unbalanced Yh1-type T cell cytokine pattern: reversal with Il-10. J Immunol 160 (1998) 3602-3609
39. Hruskova Z., Rihova Z., Mareckova H., Jancova E., Rysava R., Zavaa J., et al. Intracellular cytokine production in ANCA-associated vasculitis: low levels of interleukin-10 in remission are associated with higher relapse rate in the long-term follow-up. Arch Med Res 40 (2009) 276-284
40. Sharraf P., and Sneller M.C. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev Mol Med 7 (2005) 1-19